Media Advisories

Updates for media on the latest products, offerings and developments across our business.

View all
Filter Results
Filter Results
General (469) Financials (94) Partnerships (64) Ad hoc (44) Acquisitions (24) New Products (17) New Technologies (10)
Corporate (309) Specialized Modalities (110) Integrated Biologics (95) Capsules & Health Ingredients (62) Advanced Synthesis (28)
2026 (11) 2025 (15) 2024 (24) 2023 (25) 2022 (39) 2021 (65) 2020 (84) 2019 (100) 2018 (91) 2017 (79) 2016 (75)
English (530) Deutsch (74) French (4)
   Loading...
Showing 1‐20 of 500
09 Jun 2026
Lonza Appoints Hans Trees as Global Head of Communications
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026 Hans combines deep...
08 May 2026
Lonza Announces Results of the 2026 Annual General Meeting – All Motions Proposed by Board of Directors Approved
Jean-Marc Huët was re-elected as Chair of the Board of Directors Claudia Süssmuth-Dyckerhoff, Sami Atiya and Stephen Fry were elected as members of the Board of...
08 May 2026
Lonza gibt Ergebnisse der Generalversammlung 2026 bekannt – Alle Anträge des Verwaltungsrates wurden genehmigt
Jean-Marc Huët wurde als Präsident des Verwaltungsrates wiedergewählt Claudia Süssmuth-Dyckerhoff, Sami Atiya und Stephen Fry wurden als Mitglieder des Verwaltungsrates...
08 May 2026
Lonza¹ Delivers Strong Performance in Q1 2026 in Line with Expectations and Confirms Full-Year Outlook 2026
Strong CDMO1 performance in Q1 2026, in line with expected H1-weighted growth and Full-Year 2026 margin trajectory – despite a changing geopolitical landscape, evolving trade...
01 Apr 2026
Lonza Publishes 2026 Annual General Meeting Invitation and 2025 Annual and Sustainability Reports
Annual General Meeting will take place on 8 May 2026 at the Congress Center in Basel, Switzerland Jean-Marc Huët proposed for re-election as Chair of the Board of...
31 Mar 2026
Lonza Nominates Stephen Fry as Independent Board Member
Stephen Fry is nominated to the Lonza Board for his extensive track record in the pharma industry and deep experience in performance culture and organizational...
09 Mar 2026
Lonza and Genetix Biotherapeutics Extend Commercial Manufacturing Agreement for ZYNTEGLO™
Extended agreement will expand manufacturing capacity at Lonza Houston (US) to support growing demand for Genetix’s ZYNTEGLO™ (betibeglogene autotemcel), the only FDA-approved gene...
06 Mar 2026
Lonza Completes its Transformation to a Pure-Play CDMO with Agreement to Divest Capsules & Health Ingredients
Lonza signs agreement to divest its Capsules & Health Ingredients (CHI) business to Lone Star Funds, for an enterprise value of CHF 2.3 billion (USD 3 billion) at closing. The...
13 Feb 2026
Changes to the Composition of the Lonza Board
Sami Atiya is nominated to the Lonza Board for his deep experience in healthcare, robotics, automation and AI acquired from senior roles at ABB, Siemens and other leading...
28 Jan 2026
Lonza Delivers Strong Profitable Growth in Full-Year 2025 and Successfully Completes Vacaville Site Integration
In 2025, Lonza1 delivered sales of CHF 6.5 billion with +21.7% CER2 growth, and a CORE EBITDA of CHF 2.1 billion at a margin of 31.6% (+1.4ppts versus prior year), outperforming...
28 Jan 2026
Für das Geschäftsjahr 2025 erzielt Lonza starkes, profitables Wachstum und schliesst die Integration des Standorts Vacaville erfolgreich ab
Im Jahr 2025 erzielte Lonza1 einen Umsatz von CHF 6.5 Milliarden mit +21.7% Umsatzwachstum in kWk2 und einem Kern-EBITDA von CHF 2.1 Milliarden, was einer Marge von 31.6% (+1.4...
23 Oct 2025
Lonza Delivers a Strong Q3 2025 and Confirms Full-Year 2025 Outlook for its CDMO and CHI Businesses
Strong CDMO1 performance in Q3 2025 in Integrated Biologics and Advanced Synthesis, while Specialized Modalities improved versus a soft H1 Large contract signings in Q3, including...
03 Oct 2025
Lonza Nominates Claudia Süssmuth-Dyckerhoff as Board Member
Subject to her election at the AGM, Claudia will also be appointed Vice-Chair of the Board and a member of the Remuneration Committee Jürgen Steinemann and Barbara Richmond will...
12 Sep 2025
Lonza Appoints Jason Berndt as Head of Group Operations, and Maria Soler Nunez as Chief Quality Officer
Jason Berndt will join Lonza on 1 October 2025 as new Head of Group Operations, Executive Vice President and member of the Executive Committee (EC) Maria Soler Nunez, currently...
23 Jul 2025
​​Lonza Delivers Strong H1 2025 Performance and Upgrades 2025 Full-Year CDMO Sales and Margin Outlook​
​​Lonza Delivers Strong H1 2025 Performance and Upgrades 2025 Full-Year CDMO Sales and Margin Outlook​
23 Jul 2025
​​Lonza erzielt starkes Ergebnis im ersten Halbjahr 2025 und erhöht Umsatz- und Margenprognose für das CDMO-Geschäft im Gesamtjahr 2025​
​​Lonza Delivers Strong H1 2025 Performance and Upgrades 2025 Full-Year CDMO Sales and Margin Outlook​
27 May 2025
Lonza Publishes 2024 Comparative Financials Under One Lonza Organizational Structure
The One Lonza organizational structure became effective on 1 April 2025 and comprises three CDMO Business Platforms: Integrated Biologics, Advanced Synthesis and Specialized...
15 May 2025
Lonza Appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer
Andreas Bohrer has served as Lonza’s Group General Counsel and Company Secretary since 2015  As of 1 July 2025, Andreas joins Lonza’s Executive Committee as Chief Legal &...
09 May 2025
Lonza Announces Results of the 2025 Annual General Meeting – All Motions Proposed by Board of Directors Approved
Jean-Marc Huët was re-elected as Chair of the Board of Directors  Juan Andres, Eric Drapé and David Meline have been elected as Members of the Board of Directors Shareholders...
09 May 2025
Lonza gibt Ergebnisse der Generalversammlung 2025 bekannt – Alle Anträge des Verwaltungsrates wurden genehmigt
Jean-Marc Huët wurde als Präsident des Verwaltungsrates wiedergewählt Juan Andres, Eric Drapé und David Meline wurden als Mitglieder des Vewaltungsrates gewählt Die...